OncLive TV

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

Oleg Gluz, MD, discusses findings from subgroup analyses of the WSG-TP-II trial of neoadjuvant de-escalated chemotherapy in HER2-positive breast cancer.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.